Brown Advisory’s United Therapeutics UTHR Stock Holding History

Brown Advisory’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-10,510	Closed	-$1.23M	–	1265
2019 Q1	$1.23M	Hold	10,510	–	–	﹤0.01%	758
2018 Q4	$1.15M	Sell	10,510 -4,475	-30%	-$519K	﹤0.01%	728
2018 Q3	$1.92M	Hold	14,985	–	–	0.01%	644
2018 Q2	$1.7M	Buy	14,985 +11,985	+400%	+$1.32M	0.01%	659
2018 Q1	$337K	Sell	3,000 -250	-8%	-$31.8K	﹤0.01%	940
2017 Q4	$481K	Buy	3,250 +250	+8%	+$31.8K	﹤0.01%	887
2017 Q3	$352K	Sell	3,000 -259	-8%	-$33.1K	﹤0.01%	962
2017 Q2	$423K	Sell	3,259 -66	-2%	-$8.23K	﹤0.01%	900
2017 Q1	$450K	Hold	3,325	–	–	﹤0.01%	844
2016 Q4	$477K	Buy	3,325 +259	+8%	+$33.1K	﹤0.01%	796
2016 Q3	$362K	Sell	3,066 -32	-1%	-$3.85K	﹤0.01%	833
2016 Q2	$328K	Buy	3,098 +1,066	+52%	+$119K	﹤0.01%	839
2016 Q1	$226K	Hold	2,032	–	–	﹤0.01%	896
2015 Q4	$318K	Buy	+2,032	New	+$296K	﹤0.01%	781

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Brown Advisory's UTHR Position: Q2 2019 in Review

Brown Advisory sold out of United Therapeutics (UTHR) in Q2 2019, closing a stake of 10,510 shares — an estimated $1.23M sold.

Brown Advisory first reported a position in UTHR in Q4 2015 and held it in 14 quarters. The position peaked at $1.92M in Q3 2018. 320 funds tracked by Wall St. Rank hold UTHR as of Q2 2019.

Brown Advisory reported no remaining United Therapeutics position as of Q2 2019 after selling out during the quarter.
Brown Advisory sold 10,510 United Therapeutics shares in Q2 2019, an estimated $1.23M.
Brown Advisory first reported a position in United Therapeutics in Q4 2015 and held it in 14 quarters.
Brown Advisory's United Therapeutics position peaked at $1.92M in Q3 2018.
320 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2019.

Based on Brown Advisory's 13F filing for Q2 2019, filed 12 Aug 2019.